Validation of HPLC Method for Quantitative Determination of Gefitinib in Polymeric Nanoformulation

被引:12
作者
Navya, K. S. [1 ]
Pai, Girish K. [1 ]
Verma, Ruchi [2 ]
Ananthakrishna, Padiyar [3 ]
Kumar, Lalit [1 ]
机构
[1] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Udupi 576104, Karnataka, India
[2] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Chem, Udupi 576104, Karnataka, India
[3] Cipla Ltd, Party Qual 3, Bombay 400083, Maharashtra, India
关键词
gefitinib; polymeric nanoformulation; HPLC; method development; method validation; HUMAN PLASMA; IN-VITRO; DESIGN; QUALITY; THERAPY;
D O I
10.1007/s11094-017-1575-6
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Gefitinib was determined quantitatively in a nanoformulation using the proposed HPLC method. Effective elution was achieved by using a stationary phase of HyperClone (PhenomenexA (R)) C-18 column (250 mm x 4.6 mm i.d., 5 mu m, BDS 130 ) and a mobile phase composed of acetonitrile and 40 mM ammonium formate buffer pH 2.5 (30 : 70, %v/v) at a flow rate of 1.0 mL/min. The samples were measured at 248 nm using UV detector. The column temperature was kept at 25A degrees C; the run time was 7 min; the injection volume was 20 mu L. Gefitinib was separated within 4.476 min. The correlation coefficient for the obtained calibration curve was found to be 0.998. The method was validated according to ICH Q2 (R1) guidelines for linearity, sensitivity, robustness, accuracy and precision. The LOD and LOQ were found to be 37.852 and 114.702 ng/mL, respectively.
引用
收藏
页码:159 / 163
页数:5
相关论文
共 20 条
[1]  
[Anonymous], 2005, ICH Q2 R1 ICH HARM T
[2]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[3]   Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate [J].
Awotwe-Otoo, David ;
Agarabi, Cyrus ;
Faustino, Patrick J. ;
Habib, Muhammad J. ;
Lee, Sau ;
Khan, Mansoor A. ;
Shah, Rakhi B. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 62 :61-67
[4]   Cancer active targeting by nanoparticles: a comprehensive review of literature [J].
Bazak, Remon ;
Houri, Mohamad ;
El Achy, Samar ;
Kamel, Serag ;
Refaat, Tamer .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) :769-784
[5]   Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy? [J].
Budha, N. R. ;
Frymoyer, A. ;
Smelick, G. S. ;
Jin, J. Y. ;
Yago, M. R. ;
Dresser, M. J. ;
Holden, S. N. ;
Benet, L. Z. ;
Ware, J. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (02) :203-213
[6]  
Dolan J., 2016, GUIDE HPLC LC MS BUF, P1
[7]   A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma [J].
Faivre, Lionel ;
Gomo, Charline ;
Mir, Olivier ;
Taieb, Fabrice ;
Schoemann-Thomas, Audrey ;
Ropert, Stanislas ;
Vidal, Michel ;
Dusser, Daniel ;
Dauphin, Alain ;
Goldwasser, Francois ;
Blanchet, Benoit .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2011, 879 (23) :2345-2350
[8]   Validation of a Gas Chromatography/Mass Spectrometry Method for Quantitative Determination of Zolpidem in Whole Blood [J].
Krylova, E. A. ;
Kataev, S. S. ;
Khomov, Yu. A. ;
Dvorskaya, O. N. .
PHARMACEUTICAL CHEMISTRY JOURNAL, 2015, 49 (08) :564-569
[9]   Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles [J].
Kumar, Lalit ;
Reddy, M. Sreenivasa ;
Managuli, Renuka S. ;
Pai, Girish K. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (05) :549-555
[10]   In vitro metabolism of gefitinib in human liver microsomes [J].
Mckillop, D ;
Mccormick, AD ;
Miles, GS ;
Phillips, PJ ;
Pickup, KJ ;
Bushby, N ;
Hutchison, M .
XENOBIOTICA, 2004, 34 (11-12) :983-1000